Clinical Outcomes and Quantitative HBV Surface Antigen Levels in Diverse Chronic Hepatitis B Patients in Canada: A Retrospective Real-World Study of CHB in Canada (REVEAL-CANADA).
Carla S CoffinSarah Haylock-JacobsKaren E DoucetteAlnoor RamjiHin Hin KoDavid K WongMagdy ElkhashabRobert BaileyJulia UhanovaGerald MinukKeith TsoiAlexander WongMang M MaEdward TamMayur BrahmaniaCarmine NudoJulie ZhuChristopher F LoweCarla OsiowyB Cord LethebeStephen E ConglyEric K H ChanAngelina Villasis-KeeverUrbano SbarigiaCurtis L CooperScott FungPublished in: Viruses (2022)
In this retrospective, ethnically diverse cohort study, CHB patients who received antiviral therapy and/or had HBsAg loss were less likely to develop cirrhosis and HCC, confirming the results of the studies in less diverse cohorts. No association was found between the qHBsAg level and fibrosis determined with LSM. Individuals who achieved HBsAg loss had low-level qHBsAg within 1 year of seroclearance.